Kahira Pharmaceuticals’ profits grow 22.5% in 6 months
Updated 2/13/2022 2:10:23 PM
ArabFinance: Kahira Pharmaceuticals and Chemical Industries Company (CPCI) reported a 22.47% year-on-year growth in net profit after tax for the first half (H1) of fiscal year (FY) 2021/2022, according to the company’s unaudited financial indicators filed to the Egyptian Exchange (EGX).
CPCI’s net profit after tax stood at EGP 82.05 million for the six-month period ended December 31st 2021, compared to profits of EGP 67.004 million the year before, as per the statement.
Revenue amounted to EGP 527.10 million in H1 FY 2021/2022, down from EGP 532.23 million in the comparative period a FY earlier.
Kahira Pharmaceuticals is an Egypt-based company involved in the manufacture and trade of pharmaceutical products for human and veterinary use.
